上海口腔医学 ›› 2023, Vol. 32 ›› Issue (4): 410-416.doi: 10.19439/j.sjos.2023.04.014

• 论著 • 上一篇    下一篇

二甲双胍联合DPP-4抑制剂对2型糖尿病伴慢性牙周炎患者牙槽骨密度的影响

刘珂1, 艾合买提·艾尼娃2,3, 图尔妮萨古丽·克比尔2,3, 古丽努尔·阿吾提2,3   

  1. 1.北京市延庆区医院(北京大学第三医院延庆医院) 口腔科,北京 102100;
    2.新疆医科大学第一附属医院(附属口腔医院) 牙周黏膜病科,新疆 乌鲁木齐 830054;
    3.新疆维吾尔自治区口腔医学研究所, 新疆 乌鲁木齐 830054
  • 收稿日期:2022-01-25 修回日期:2022-05-08 发布日期:2023-09-07
  • 通讯作者: 古丽努尔·阿吾提,E-mail:guawuti@sina.com
  • 作者简介:刘珂(1995-),女,硕士,住院医师,E-mail:1564613855@qq.com
  • 基金资助:
    中华口腔医学会西部口腔医学临床科研基金(CSA-W2020-11)

Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis

LIU Ke1, AHEMAITI Aniwa2,3, TUERNISAGULI Kebier2,3, GULINUER Awut2,3   

  1. 1. Department of Stomatology, Peking University Third Hospital Yanqing Hospital. Beijing102100;
    2. Department of Periodontal, Oral Mucosal Diseases, The First Affiliated Hospital of Stomatology, Xinjiang Medical University. Urumqi830054;
    3. Institute of Stomatology, Xinjiang Uygur Autonomous Region. Urumqi830054, Xinjiang Uygur Autonomous Region, China
  • Received:2022-01-25 Revised:2022-05-08 Published:2023-09-07

摘要: 目的 探讨二甲双胍联合二肽基肽酶4(DPP-4)抑制剂对2型糖尿病伴慢性牙周炎患者牙周组织的影响。方法 选择2型糖尿病伴慢性牙周炎患者80例,利用随机数字表法随机分为A组和B组,每组各40例。A组口服二甲双胍同时进行牙周基础治疗;B组在A组的基础上同时口服DPP-4抑制剂。测量2组患者治疗前(T0)及治疗后3个月(T1)、6个月(T2)的牙槽骨密度(BMD)、牙周探诊深度(PD)、临床附着丧失(CAL)、探诊出血(BOP)、糖化血红蛋白(HbA1c)、血磷、血钙、脂联素(ADP)、瘦素(LEP)、白细胞介素6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)等指标。采用SPSS 23.0软件包对数据进行统计学分析。结果 T0时,2组各临床指标均无显著差异;T1、T2时,B组的PD、CAL、BOP、HbAlc显著低于A组(P<0.05);B组的BMD显著高于A组(P<0.05);B组的炎症细胞因子水平(IL-6、CRP、TNF-α)、LEP水平显著低于A组,ADP水平显著高于A组(P<0.05)。结论 二甲双胍联合DPP-4抑制剂可使2型糖尿病伴慢性牙周炎患者牙槽骨密度增加,并有效改善牙周临床指标和血清生化指标,减轻牙周组织炎症。

关键词: 2型糖尿病, 牙周炎, 二甲双胍, 脂联素, DPP-4抑制剂

Abstract: PURPOSE: To investigate the effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis. METHODS: A total of 80 patients with type 2 diabetes mellitus and chronic periodontitis were selected and randomly divided into group A and group B by random number table, with 40 patients in each group. Group A (medication alone group): oral metformin and basic periodontal treatment; Group B (combination group): DPP-4 inhibitor (sitagliptin) was taken orally in addition to group A. Before treatment (T0) and 3 months (T1) and 6 months (T2) after treatment, alveolar bone mineral density (BDM), periodontal probing depth (PD), clinical attachment loss(CAL), probing bleeding (BOP), glycated hemoglobin (HbA1c), serum phosphorus, serum calcium, adiponectin (ADP), leptin (LEP), interleukin-6 (IL-6), C-reactive protein (HS-CRP), tumor necrosis factor (TNF-α) were detected. SPSS 23.0 software package was used for data analysis. RESULTS: Three and 6 months after treatment, PD, CAL, BOP and HbAlc in group B were significantly lower than those in group A(P< 0.05). BDM in group B was significantly higher than that in group A (P< 0.05). Compared with group A, the levels of inflammatory cytokines (IL-6, Hs-CRP, TNF-α) and leptin in group B were significantly decreased, while the level of adiponectin was significantly increased (P< 0.05). CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.

Key words: Type 2 diabetes mellitus, Periodontitis, Metformin, Adiponectin, DPP-4 inhibitor

中图分类号: